Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula (1):

~~[~~Formula 1~~]~~



(1)

wherein

R^1, R^2 and R^5 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group which may be substituted with one or more halogen atoms and a C_1-C_6 alkoxy group which may be substituted with one or more halogen atoms;

R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, -NRfRg, -CONRfRg, -CH=NORe, a C_1-C_6 alkoxy group, a C_1-C_6 alkyl group and -T-$(CH_2)_k$-V, wherein the alkyl group and the alkoxy group may be substituted with one or more substituents selected from a hydroxyl group, a C_1-C_6 alkoxy group, a halogen atom and -NRfRg;

wherein

Re is selected from a hydrogen atom and C_1-C_6 alkyl, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a C_1-C_6 alkoxy group, a halogen atom and -NRhRi,

Rf and Rg are each independently selected from a hydrogen atom, C_1-C_6 alkyl group and C_1-C_6 alkylcarbonyl group, wherein the alkyl group and the alkylcarbonyl group may be substituted with one to three substituents selected from a hydroxyl group, a C_1-C_6 alkoxy group, a halogen atom and -NRhRi,

Rh and Ri are each independently selected from a hydrogen atom and C_1-C_6 alkyl group, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a halogen atom and a C_1-C_6 alkoxy group, or

Rf and Rg, and Rh and Ri together with a nitrogen atom to which they are attached may form a 4- to 7-heterocycle, wherein the heterocycle may be substituted with a C_1-C_6 alkyl group,

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more Y^3, -NRaRb,

CONRaRb, -OC(=O)NRaRb, -SO_2NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -C(=O)ORd, -S(=O)$_m$-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -N(Ra)SO_2Rc, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -C(=O)Rc;

R^6 and R^7 are each independently selected from a hydrogen atom and a halogen atom;

Z^1 and Z^2 are each independently selected from a hydrogen atom, a hydroxyl group and -O(CHR^{11})OC(=O)R^{12};

wherein

R^{11} is a hydrogen atom or a C_1-C_6 alkyl group;

R^{12} is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino C_1-C_6 alkyl group, a mono- or di(C_1-C_6 alkyl)amino C_1-C_6 alkyl group, an amino C_1-C_6 alkylamino group or a mono- or di(C_1-C_6 alkyl)-amino C_1-C_6 alkylamino group;

Q is a group of ~~the formula:~~

~~[Formula 2]~~



wherein

G^1 is C-Y^2 or N;

ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle; a nitrogen atom present in the heterocycle may be an N-oxide; and the ring A may be substituted with one to three same or different substituents W;

Y^1 and Y^2 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group, a C_2-C_6 alkenyl group, a C_1-C_6 alkoxy group, a mono- or dihydroxy C_1-C_6 alkyl group, a C_1-C_6 alkoxy C_1-C_6 alkoxy group, an amino C_1-C_6 alkoxy group, a (C_1-C_6 alkyl)amino C_1-C_6 alkoxy group, a di(C_1-C_6 alkyl)amino C_1-C_6 alkoxy group, a C_1-C_6 alkoxy C_1-C_6 alkyl group, an amino C_1-C_6 alkyl group, a (C_1-C_6 alkyl)amino C_1-C_6 alkyl group, a di(C_1-C_6 alkyl)amino C_1-C_6 alkyl group, an amino group, a (C_1-C_6 alkyl)amino group and a di(C_1-C_6 alkyl)amino group;

W is a halogen atom, a nitro group, a cyano group, a hydroxyl group, -NRaRb, -N=C(-Rc)NRaRb, -CONRaRb, -OC(=O)NRaRb, $-SO_2$NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -N[C(=O)ORd][C(=O)ORd'], -C(=O)ORd, $-S(=O)_m$-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -N[C(=O)Rc][C(=O)Rc'], -N(-Ra)SO_2Rc, -N(SO_2Rc)(SO_2Rc'), -C(=NORd)NRa'Rb', -C(=NRa)NRa'Rb', -C(=NORa)Rc, -C(=O)Rc, a C_1-C_6 alkyl

group which may be substituted with one or more Y^3, a C_2-C_7 alkenyl group which may be substituted with one or more Y^3, a C_2-C_7 alkynyl group which may be substituted with one or more Y^3, an aryl group which may be substituted with one or more Y^3 or a heteroaryl group which may be substituted with one or more Y^3;

Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' are each independently selected from a hydrogen atom, a C_1-C_{10} alkyl group, a C_3-C_8 cycloalkyl group, a C_2-C_8 alkenyl group, a C_2-C_8 alkynyl group, -[(C_1-C_6 alkylene)-O]$_n$-(C_1-C_3 alkyl), a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a C_1-C_3 alkyl group); or

Ra and Rb, Ra' and Rb', Ra and Rd, Ra and Ra', Ra and Rc, Rc and Rc', and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a C_1-C_6 alkyl group;

Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' each may be substituted with one to three same or different substituents selected from Y^3;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

Y^3 is a halogen atom, -NRxRy, -C(=O)ORz, -C(=O)Rz, -ORz, -C(=O)NRxRy, -OC(=O)NRxRY, $-SO_2NRxRy$, -N(-Rx)C(=O)NRx'Ry', -N(-Rx)C(=O)ORz, -S-Rz, -SO-Rz, $-SO_2-Rz$, -OC(=O)Rz, -N(Rx)C(=O)Rz, -C(=NORz)NRx'Ry', -C(=NRx)NRx'Ry', -C(=NORx)Rz, -[O-(C_1-C_6 alkylene)]$_n$-O(C_1-C_3 alkyl), -N(-Rx)-(C_1-C_6 alkylene)-O(C_1-C_3 alkyl), -C(=O)Rz, a C_1-C_6 alkyl group, a C_2-C_8 alkenyl group, a C_2-C_8 alkynyl group, an aryl group or a heteroaryl group;

Rx, Rx', Ry, Ry' and Rz are each independently selected from a hydrogen atom and a C_1-C_4 alkyl group;

Rx and Ry, Rx and Rx', Rx and Rz, and Rz and Rx' may form a saturated or unsaturated 5-to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups;

a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. (Original) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein R^2 is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.

3. (Currently Amended) The compound of claim 1~~ or claim 2~~, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q is a group of the formula selected from~~:~~

~~[~~Formula 3~~]~~



which may be substituted with one to three same or different substituents W.

4. (Currently Amended) The compound of ~~any one of~~ claim~~s~~ 1~~ to 3~~, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q is a group of the formula selected from:

~~[~~Formula 4~~]~~



which may be substituted with one to three same or different substituents W.

5. (Currently Amended) The compound of ~~any one of~~ claim~~s~~ 1~~ to 4~~, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein Q is a group of the formula selected from:

~~[~~Formula 5~~]~~



which may be substituted with one to three same or different substituents W.

6. (Currently Amended) The compound of ~~any one of~~ claim~~s~~ 1~~ to 5~~, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^1, R^2, R^3, R^4 and R^5 are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

R^6 and R^7 are hydrogen atoms; and

Z^1 and Z^2 are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Currently Amended) The compound of ~~any one of~~ claims ~~1 to 5~~, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group which may be substituted with one or more hydroxyl groups or halogen atoms, a C_1-C_6 alkoxy group which may be substituted with one or more halogen atoms, and -T-$(CH_2)_k$-V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-menbered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C_1-C_6 alkyl group, C_1-C_6 alkoxy group and C_1-C_6 alkylcarbonyl group.

8. (Currently Amended) A compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of ~~any one of~~ claims ~~1 to 7~~ which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating

cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. (Currently Amended) A pharmaceutical composition comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of ~~any one of~~ claim~~s~~ 1~~ to 7~~ as an active ingredient.

10. (Currently Amended) An Raf inhibitor or an angiogenesis inhibitor comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of ~~any one of~~ claim~~s~~ 1~~ to 7~~ as an active ingredient.

11. (Currently Amended) A preventive or therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of ~~any one of~~ claim~~s~~ 1~~ to 7~~ as an active ingredient.

12. (New) A method for treating a patient in need of Raf inhibition or angiogenesis inhibition comprising administering to said patient an effective amount of a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1.

13. (New) The method according to claim 12 wherein the patient is suffering from at least one condition selected form the group consisting of cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.